Beyond pancreatic effects, GIP receptor agonism enhances peripheral insulin sensitivity, particularly in adipose tissue, where it promotes healthy white adipose tissue (WAT) expansion, facilitates dietary triglyceride clearance through increased lipoprotein lipase activity and adipose blood flow, and improves lipid buffering capacity [40]
It is worth understanding that brand-name semaglutide is manufactured under strict FDA oversight with standardized concentrations, while compounded versions are produced by pharmacies operating under different regulatory frameworks
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight
Call 918-786-3686 for more information